Gene · 92521
Papers3,158
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 3,158
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Spatial Transcriptomics and Single Cell-RNASeq Reveals Cellular Heterogeneity of SARS-CoV-2 in Lung Tissues and Global Mutational Patterns in COVID-19 Patients. | J Med Virol | 2025 | 40910395 | PubTator, text mining | PubMed |
| A Super-Resolution Spatial Atlas of SARS-CoV-2 Infection in Human Cells. | bioRxiv | 2025 | 40894656 | PubTator, text mining | PubMed |
| PRRSV evades innate immune cGAS-STING antiviral function via its Nsp5 to deter STING translocation and activation. | Virulence | 2025 | 40842188 | PubTator, text mining | PubMed |
| The NSP5, ORF6 and NSP13 of SARS-CoV-2 Cooperate to Modulate Inflammatory Cell Death Activation. | Adv Sci (Weinh) | 2025 | 40810650 | PubTator, text mining | PubMed |
| A luminescent attenuated SARS-CoV-2 for the identification and validation of drug-resistant mutants. | J Virol | 2025 | 40772686 | PubTator, text mining | PubMed |
| Structural Dynamics of SARS-CoV-2 NSP4 C-terminal Domain and Implications for Viral Processing. | J Mol Biol | 2025 | 40763845 | PubTator, text mining | PubMed |
| The main protease (Mpro) from SARS-CoV-2 triggers plasma clotting in vitro by activating coagulation factors VII and FXII. | Commun Biol | 2025 | 40750828 | PubTator, text mining | PubMed |
| The protease inhibitor Nirmatrelvir synergizes with inhibitors of GRP78 to suppress SARS-CoV-2 replication. | Antiviral Res | 2025 | 40744403 | PubTator, text mining | PubMed |
| The P132H mutation of SARS-CoV-2 NSP5 relieves its inhibition on interferon-β activation via blocking MAVS degradation. | Cell Mol Life Sci | 2025 | 40736574 | PubTator, text mining | PubMed |
| A single mutation may contribute to accelerated evolution of SARS-CoV-2 toward Omicron. | Nat Commun | 2025 | 40730568 | PubTator, text mining | PubMed |
| Differential severity of SARS-CoV-2 variant infections in children and adults with COVID-19. | J Clin Virol | 2025 | 40674918 | PubTator, text mining | PubMed |
| Antiviral efficacy of hexane extract of Hypericum gaitii Haines against Chikungunya and SARS-CoV-2 viruses: in vitro and in silico approaches. | J Ethnopharmacol | 2025 | 40651726 | PubTator, text mining | PubMed |
| Porcine reproductive and respiratory syndrome virus NSP5 exploited UBE2L6 to promote viral replication via antagonising host RLRs and ISGylation. | Vet Res | 2025 | 40611336 | PubTator, text mining | PubMed |
| Uncovering protein conformational dynamics within two-component viral biomolecular condensates. | Protein Sci | 2025 | 40521608 | PubTator, text mining | PubMed |
| Strategy to overcome a nirmatrelvir resistance mechanism in the SARS-CoV-2 nsp5 protease. | Sci Adv | 2025 | 40479048 | PubTator, text mining | PubMed |
| Wastewater sequencing from a rural community enables identification of widespread adaptive mutations in a SARS-CoV-2 alpha variant. | Sci Rep | 2025 | 40437225 | PubTator, text mining | PubMed |
| Identification and targeting of regulators of SARS-CoV-2-host interactions in the airway epithelium. | Sci Adv | 2025 | 40378209 | PubTator, text mining | PubMed |
| Development of a magnetic beads-based ligand fishing method for screening SARS-CoV-2 NSP5 inhibitors from complex herbal mixtures: Rosmarinus officinalis as a case study. | J Chromatogr A | 2025 | 40300453 | PubTator, text mining | PubMed |
| Targeted protein degraders of SARS-CoV-2 Mpro are more active than enzymatic inhibition alone with activity against nirmatrelvir resistant virus. | Commun Med (Lond) | 2025 | 40287552 | PubTator, text mining | PubMed |
| Cholesterol-dependent Nsp5-endosomes co-trafficking to lysosomes facilitates porcine reproductive and respiratory syndrome virus replication by activating autophagy. | Vet Microbiol | 2025 | 40215803 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/92521/papers?page=5